Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Rifaximin (Xifaxanta®) is recommended as an option for use within NHS Wales for the treatment of travellers’ diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool or to shorten the duration of diarrhoea when this is associated with non-invasive strains of E. coli. |
|||
|
|||
Medicine details |
|||
| Medicine name | rifaximin (Xifaxanta®) | ||
| Formulation | 200 mg film-coated tablet | ||
| Reference number | 1232 | ||
| Indication | Treatment of travellers diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool. Rifaximin may shorten the duration of diarrhoea when this is associated with non-invasive strains of E. coli |
||
| Company | Norgine Pharmaceuticals Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 1212 | ||
| NMG meeting date | 15/05/2012 | ||
| AWMSG meeting date | 20/06/2012 | ||
| Ratification by Welsh Government | 23/07/2012 | ||
| Date of issue | 27/07/2012 | ||
| Date of last review | 30/08/2016 | ||